Why the study?
The pathogenesis of AF remains unclear, but VEGFs stimulate cardiac fibrosis. The study evaluated whether serum VEGF/sVEGFR levels relate to AF in patients with valvular heart disease.
Are plasma levels of circulating vascular endothelial growth factors (VEGFs) and their soluble receptors associated with atrial fibrillation in patients with valvular heart disease?
Are plasma levels of circulating vascular endothelial growth factors (VEGFs) and their soluble receptors associated with atrial fibrillation in patients with valvular heart disease?
An imbalance in circulating VEGFs and sVEGFRs, particularly lower sVEGFR-2, is associated with atrial fibrillation in patients with valvular heart disease, suggesting a potential biomarker role.
Answers are grounded in this paper and cite their sources.
May link VEGFs to AF in VHD; hypothesis-generating and requires prospective validation before clinical consideration.
BACKGROUND: The pathogenesis of atrial fibrillation (AF) remains unclear. Vascular endothelial growth factors (VEGFs) can stimulate fibrosis within the atrium and ventricle. We hypothesized that there is a relationship between the serum VEGFs/soluble vascular endothelial growth factor receptor (sVEGFRs) levels and AF in patients with valvular heart disease (VHD). This provides a new paradigm for studying AF. METHODS: The plasma levels of VEGF-A, VEGF-C, sVEGFR-1 and sVEGFR-2 were detected by enzyme-linked immunosorbent assay (ELISA). A total of 100 people, consisting of AF patients (long-standing, persistent AF; n=49), sinus rhythm (SR) patients (n=31) and healthy controls (n=20), were included in this study. RESULTS: The plasma levels of VEGF-A were significantly higher in AF patients compared to healthy control (P<0.05). The plasma levels of sVEGFR-1 were significantly higher in AF compared to SR (P<0.05). The plasma levels of sVEGFR-2 were significantly lower in AF patients compared to SR patients and healthy controls (both P<0.05). There was a significant and negative correlation between AF and the sVEGFR-2 levels in the groups (r=-0.432, P=0.000). CONCLUSIONS: An imbalance in VEGFs and sVEGFRs may contribute to AF by breaking the balance of angiogenesis and lymphangiogenesis. Additionally, sVEGFR-2 may be an important biomarker of AF.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: